Molecular Diagnostics and Therapeutic Approaches in Zoonotic Infections

Dr. Densingh Johnrose., Mihir Sharma., Azaruddin Gohil., Shivam Singh

Department of Microbiology, SDIS

DOI: https://doi.org/10.51584/IJRIAS.2025.10060054

Received: 04 June 2025; Accepted: 14 June 2025; Published: 07 July 2025

ABSTRACT

Zoonotic infections—diseases naturally transmitted between animals and humans—represent over 60% of emerging infectious diseases globally. The increasing frequency of zoonotic outbreaks, driven by factors such as globalization, environmental change, and intensified human–animal interactions, underscores the urgent need for robust diagnostic and therapeutic strategies. Traditional diagnostic tools, while useful, often lack the sensitivity, specificity, and speed required to manage emerging zoonoses effectively. In response, molecular diagnostics have revolutionized the detection and characterization of zoonotic pathogens. Techniques such as real-time polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), next-generation sequencing (NGS), and CRISPR-based assays have enabled rapid, accurate, and high-throughput identification of a broad spectrum of zoonotic agents. These technologies not only facilitate early detection but also support genomic surveillance, antimicrobial resistance profiling, and outbreak tracking.

Parallel to diagnostic advances, therapeutic strategies have evolved significantly. Conventional approaches—including antimicrobial agents and supportive therapy—are now being complemented by innovative modalities such as monoclonal antibodies, host-directed therapies, and next-generation vaccine platforms, including mRNA and viral vector-based vaccines. These therapeutics have shown promise in controlling infections like COVID-19, rabies, and Ebola. However, the development and equitable distribution of such interventions remain a challenge, particularly in low-resource settings.

This review critically examines current and emerging molecular diagnostic tools and therapeutic strategies for key zoonotic infections. It highlights case studies of major zoonotic outbreaks, discusses the translational potential of novel technologies, and emphasizes the necessity of an integrated One Health approach that considers the interconnectedness of human, animal, and environmental health. Strengthening molecular surveillance and treatment capabilities worldwide will be essential to mitigate the global burden of zoonoses and to prevent future pandemics.

Keywords: polymerase chain reaction, mRNA, viral vector-based vaccines

INTRODUCTION

Zoonotic infections—diseases that are transmissible between animals and humans—represent a critical and growing challenge to global public health, accounting for more than 60% of all emerging infectious diseases worldwide. Historical and contemporary outbreaks such as the plague, avian influenza, Ebola virus disease, and the COVID-19 pandemic are striking examples of how zoonotic pathogens can rapidly cross species barriers and cause widespread morbidity, mortality, and socio-economic disruption. The increasing frequency of such events is closely linked to several converging global trends, including deforestation, urbanization, climate change, wildlife trade, agricultural intensification, and increased human encroachment into natural habitats.

Effective management of zoonotic diseases requires timely and accurate detection of the causative agents, alongside the deployment of appropriate therapeutic interventions. Traditional diagnostic methods such as culture techniques, microscopy, and serological assays, while foundational, often suffer from limitations

ISSN No. 2454-6194 | DOI: 10.51584/IJRIAS |Volume X Issue VI June 2025

related to sensitivity, specificity, and turnaround time. These challenges can lead to diagnostic delays, contributing to underreporting, inappropriate treatment, and unchecked transmission.

Recent advances in molecular diagnostics have significantly transformed the landscape of zoonotic disease detection. Techniques such as real-time polymerase chain reaction (RT-PCR), loop-mediated isothermal amplification (LAMP), next-generation sequencing (NGS), and CRISPR-based diagnostic platforms offer unprecedented speed, sensitivity, and scalability. These technologies enable not only early and precise identification of pathogens but also real-time genomic surveillance, antimicrobial resistance profiling, and outbreak source tracking capabilities that are essential for effective disease control.

In parallel, the field of therapeutics has undergone rapid innovation. In addition to conventional antimicrobial and antiviral agents, emerging therapies include monoclonal antibodies, host-targeted treatments, and next-generation vaccines, such as mRNA and viral vector-based platforms. These innovations have demonstrated high efficacy in recent zoonotic outbreaks, including COVID-19 and Ebola virus disease, and continue to evolve in response to new threats.

This paper aims to provide a comprehensive review of the current and emerging molecular diagnostic tools and therapeutic strategies for zoonotic infections. By exploring both technological advancements and practical implementation challenges, the review underscores the importance of an integrated, multidisciplinary approach—aligned with the One Health framework—to effectively predict, detect, and respond to zoonotic threats.

Overview of Zoonotic Infections

Classification and Epidemiology

Zoonotic infections encompass a wide array of pathogens that cross the species barrier between animals and humans. These infections can be caused by bacteria, viruses, parasites, or fungi, each with unique transmission dynamics, reservoirs, and geographical distributions. The global burden of zoonotic diseases is particularly high in low- and middle-income countries, where close human–animal interaction, inadequate health infrastructure, and limited diagnostic capacity increase vulnerability to outbreaks.

Bacterial Zoonoses

Bacterial zoonoses are among the most commonly reported globally. *Brucellosis*, caused by *Brucella spp.*, is typically transmitted through contact with infected livestock or consumption of unpasteurized dairy products. It presents with flu-like symptoms but can progress to chronic illness if untreated. *Leptospirosis*, caused by *Leptospira interrogans*, is another widespread bacterial zoonosis, transmitted through contact with water or soil contaminated by the urine of infected animals. Outbreaks are common in tropical climates, particularly after flooding.

Viral Zoonoses

Viral zoonoses pose significant public health threats due to their potential for human-to-human transmission and pandemic spread. *Rabies*, a nearly always fatal disease if not promptly treated, is transmitted via the bite of infected mammals, especially dogs in endemic regions. *Hantavirus* infections, transmitted via rodent excreta, cause severe respiratory illness. Notably, coronaviruses such as *SARS-CoV*, *MERS-CoV*, and *SARS-CoV-2* have demonstrated how zoonotic viruses can rapidly evolve and result in global pandemics.

Parasitic Zoonoses

Parasitic infections like *toxoplasmosis* (caused by *Toxoplasma gondii*) and *leishmaniasis* (caused by *Leishmania spp.*) continue to affect millions worldwide. *Toxoplasmosis* is typically acquired through ingestion of undercooked meat or contact with contaminated cat feces, while *leishmaniasis* is transmitted via sand-fly vectors and is endemic in parts of Africa, Asia, and South America.

ISSN No. 2454-6194 | DOI: 10.51584/IJRIAS |Volume X Issue VI June 2025

Fungal Zoonoses

Fungal zoonoses are less common but can be severe, especially in immunocompromised individuals. *Histoplasmosis*, caused by *Histoplasma capsulatum*, is contracted through inhalation of fungal spores found in bat or bird droppings. The disease is endemic in specific regions such as the Ohio and Mississippi River valleys in the United States.

Table 1: Classification and Epidemiology of Major Zoonotic Infections

Category	Pathogen	Common Reservoir(s)	Geographic Distribution	Mode of Transmission	Key Clinical Features
Bacterial	Brucella spp	Livestock (cattle, goats)	Mediterranean, Middle East, Asia	Direct contact, ingestion	Fever, malaise, arthritis
Viral	Rabies virus	Bats, dogs, wild carnivores	Worldwide (esp. Asia, Africa)	Animal bites	Encephalitis, hydrophobia
Parasitic	Toxoplasma gondii	Cats	Worldwide	Ingestion of oocysts, congenital	Flu-like symptoms, congenital defects
Fungal	Toxoplasma gondii	Bats, birds	Americas, Africa, Asia	Inhalation of spores	Pulmonary infection

Transmission Pathways

Understanding the transmission pathways of zoonotic infections is crucial for designing preventive strategies and containment policies. These pathways include:

Direct Contact

Many zoonoses are transmitted through direct contact with the bodily fluids, tissues, or excretions of infected animals. This route is particularly relevant for individuals working in animal husbandry, veterinary medicine, or wildlife conservation. Rabies, brucellosis, and anthrax are classic examples of direct-contact transmission.

Vector-Borne Transmission

Some zoonotic diseases require an intermediate arthropod vector for transmission. For example, *leishmaniasis* is spread by the bite of infected sandflies, while *plague* is transmitted by fleas. Vector-borne transmission adds complexity to disease control, as it involves ecological and climatic factors influencing vector populations.

Foodborne and Waterborne Routes

Contaminated food and water are major routes for several zoonotic infections. Ingestion of undercooked or raw animal products, such as meat or unpasteurized milk, can transmit pathogens like *Salmonella*, *Campylobacter*, *Toxoplasma gondii*, and *Brucella spp.* Leptospirosis and cryptosporidiosis are commonly associated with contaminated water sources, especially during natural disasters or in areas with poor sanitation.

Molecular Diagnostic Tools

Accurate and timely diagnosis of zoonotic infections is pivotal for effective clinical management and public health intervention. Traditional diagnostic methods, including culture and serology, often lack the sensitivity and specificity required for early detection, particularly during the incubation period or in asymptomatic carriers. Molecular diagnostic technologies have transformed the landscape of infectious disease diagnosis by enabling the rapid and precise identification of pathogens at the genetic level. This section explores key molecular tools currently employed in the detection of zoonotic pathogens.

ISSN No. 2454-6194 | DOI: 10.51584/IJRIAS |Volume X Issue VI June 2025

Molecular Diagnostic Tools

Accurate and timely diagnosis of zoonotic infections is pivotal for effective clinical management and public health intervention. Traditional diagnostic methods, including culture and serology, often lack the sensitivity and specificity required for early detection, particularly during the incubation period or in asymptomatic carriers. Molecular diagnostic technologies have transformed the landscape of infectious disease diagnosis by enabling the rapid and precise identification of pathogens at the genetic level. This section explores key molecular tools currently employed in the detection of zoonotic pathogen

Polymerase Chain Reaction (PCR) and Reverse Transcription PCR (RT-PCR)

PCR and RT-PCR are among the most widely adopted molecular diagnostic techniques for zoonotic diseases. PCR amplifies specific DNA sequences, making it highly effective for identifying bacterial and protozoal infections. RT-PCR, an adaptation that allows for RNA detection, is particularly useful for diagnosing viral infections. For instance, RT-PCR became the global gold standard for detecting SARS-CoV-2 during the COVID-19 pandemic due to its exceptional **sensitivity, specificity, and quantitative capabilities**.

These methods are advantageous for their ability to provide results within hours, their scalability in automated platforms, and their compatibility with a wide range of clinical samples. However, they often require laboratory infrastructure and trained personnel, limiting accessibility in low-resource settings.

Loop-mediated Isothermal Amplification (LAMP)

LAMP is a **rapid, low-cost, and field-deployable** molecular diagnostic technique that amplifies nucleic acids under isothermal conditions, eliminating the need for thermo cycling equipment. It offers **comparable sensitivity to PCR** and is well-suited for point-of-care applications in rural and remote areas.

LAMP has been successfully employed in detecting pathogens such as *Leptospira*, *Brucella*, and *Trypanosoma*, making it a valuable tool for surveillance of zoonoses in endemic regions. The visual readout (color change or fluorescence) enhances its usability in non-laboratory environments.

Next-Generation Sequencing (NGS)

NGS enables high-throughput sequencing of entire microbial genomes, facilitating **pathogen discovery, strain differentiation, and real-time outbreak surveillance**. It has played a crucial role in identifying novel zoonotic viruses such as SARS-CoV-2 and tracking their mutation patterns and transmission dynamics.

Table 2: Molecular Diagnostic Tools for Zoonotic Infections

Diagnostic Tool	Target	Pathogens Detected	Advantages	Limitations	Typical Use Cases
PCR / RT-PCR	DNA/RNA	SARS-CoV-2, Leptospira, Brucella	High sensitivity and specificity	Requires lab infrastructure	Confirmatory diagnosis, surveillance
LAMP	DNA/RNA	Leptospira, Trypanosoma	Rapid, portable, cost-effective	Primer design complexity	Field diagnosis in low-resource areas
Next-Generation Sequencing	Whole genome	Emerging viruses, unknown pathogens	Comprehensive, pathogen discovery	Expensive, data analysis intensive	Outbreak investigation, research
CRISPR-based Diagnostics	RNA/DNA	SARS-CoV-2, Dengue	Point-of-care, rapid	Early-stage development	Rapid POC testing
Serological Assays (ELISA)	Antibodies/antigens	Brucellosis, Toxoplasmosis	Cost-effective, large-scale screening	Cross-reactivity, retrospective	Epidemiology, exposure assessment

ISSN No. 2454-6194 | DOI: 10.51584/IJRIAS |Volume X Issue VI June 2025

Table 3: Therapeutic Approaches in Zoonotic Infections

Therapeutic Strategy	Examples	Target Pathogens	Mechanism of Action	Current Status	Limitations/ Challenges
Antimicrobial Agents	Doxycycline, Rifampin	Leptospira, Brucella	Bacterial inhibition	Standard treatment	Resistance, side effects
Antiviral Agents	Remdesivir, Favipiravir, Paxlovid	SARS-CoV-2, RNA viruses	Viral replication inhibition	Approved or emergency use	Limited spectrum, side effects
Monoclonal Antibodies	Rabies immunoglobulin, COVID-19 mAbs	Rabies virus, SARS-CoV-2	Neutralization of virus	Approved/under clinical trial	Cost, delivery challenges
Vaccines	mRNA (Moderna, Pfizer), Viral vectors	SARS-CoV-2, Ebola, Nipah virus	Induction of immune response	Widely deployed/experimental	Cold chain requirements, coverage
Host-Directed Therapies	Tocilizumab, JAK inhibitors	Severe viral infections	Modulate host immune response	Emergency use in COVID-19	Risk of immunosuppression

NGS also supports **metagenomic analysis**, which is especially useful in detecting unknown or unexpected pathogens in complex biological samples. While its cost and technical requirements are barriers to widespread use, the development of portable sequencers and cloud-based bioinformatics platforms is rapidly increasing its accessibility.

CRISPR-Based Diagnostics

CRISPR technology, originally developed for gene editing, has been repurposed for **ultrasensitive molecular diagnostics**. Platforms such as **SHERLOCK** (Specific High-sensitivity Enzymatic Reporter unlocking) and **DETECTR** (DNA Endonuclease-Targeted CRISPR Trans Reporter) use CRISPR-associated enzymes (Cas12, Cas13) to detect specific nucleic acid sequences.

These assays can be performed with minimal equipment and provide rapid results, often within 30–60 minutes. CRISPR diagnostics have shown potential for **point-of-care testing** of zoonotic diseases including COVID-19, dengue, and Zika virus. Ongoing research aims to expand their use to bacterial and parasitic infections.

Serological and Biosensor-Based Assays

Serological assays detect host antibodies or antigens and are commonly used for surveillance and retrospective diagnosis. **ELISA (enzyme-linked immunosorbent assay)** is a staple in diagnosing infections such as brucellosis, leptospirosis, and toxoplasmosis. It is scalable, cost-effective, and useful for evaluating population-level exposure.

Lateral flow assays (LFAs) offer rapid, visually interpretable results at the point of care. They were widely deployed for COVID-19 antigen and antibody detection and continue to be developed for other zoonoses.

Electrochemical and optical biosensors represent an emerging frontier, combining sensitivity with portability. These devices can detect pathogen-specific biomarkers in blood, saliva, or urine, and are being integrated with smartphone-based technologies to enhance real-time diagnostics in resource-limited settings.

Therapeutic Approaches

The management of zoonotic infections requires a multipronged approach that includes pathogen-targeted treatments, supportive care, immunotherapy, and vaccination. As many zoonotic diseases have no specific cures, therapeutic strategies focus on reducing viral or microbial load, modulating the host immune response, and preventing disease progression. Recent technological advances and lessons from emerging outbreaks have

ISSN No. 2454-6194 | DOI: 10.51584/IJRIAS |Volume X Issue VI June 2025

catalyzed the development of novel therapeutics aimed at improving clinical outcomes and curbing transmission.

Antimicrobial and Antiviral Agents

Antimicrobial therapy remains the first-line treatment for bacterial and some protozoal zoonoses. **Doxycycline**, a broad-spectrum tetracycline antibiotic, is widely used in the treatment and prophylaxis of **leptospirosis** and **rickettsial infections**. Similarly, **rifampin** and **streptomycin** are used in the treatment of **brucellosis**, often in combination therapy to prevent relapse.

For viral zoonoses, several **antiviral agents** have been developed or repurposed. **Remdesivir**, a nucleotide analog, has shown efficacy against **SARS-CoV-2** and was one of the first antivirals approved during the COVID-19 pandemic. **Favipiravir**, originally developed for influenza, has been used off-label for a range of RNA viruses, including **Ebola** and **Lassa fever**. **Paxlovid**, a combination of nirmatrelvir and ritonavir, has been authorized for early outpatient treatment of COVID-19 and is under evaluation for other zoonotic viruses.

Limitations of these treatments include potential resistance, side effects, and limited efficacy in advanced disease stages. Hence, early diagnosis and timely initiation of therapy are critical.

Monoclonal Antibodies and Immunotherapies

Monoclonal antibody (mAb) therapies represent a major advancement in the treatment of zoonotic viral infections. **Rabies immunoglobulin**, administered alongside rabies vaccine, provides immediate passive immunity to individuals exposed to the virus. In the context of COVID-19, multiple monoclonal antibody **cocktails** (e.g., casirivimab and imdevimab) have been developed to neutralize the virus by targeting the spike protein.

Beyond neutralization, mAbs are being designed for **post-exposure prophylaxis**, **disease mitigation**, and even as **prophylactic agents** in high-risk populations. Similar strategies are being investigated for **Ebola**, **hantavirus**, and **Zika virus**, with several candidates showing promise in clinical trials.

Vaccine Development

Vaccination remains the most cost-effective strategy for preventing zoonotic infections. Recent innovations have significantly accelerated vaccine development timelines and broadened the scope of target pathogens.

mRNA vaccines, such as those developed by **Moderna** and **Pfizer-BioNTech**, demonstrated the rapid development potential and high efficacy in combating **SARS-CoV-2**. These vaccines deliver genetic instructions for viral antigen expression, inducing strong humoral and cellular immune responses.

DNA vaccines and **viral vector-based vaccines** (e.g., Oxford-AstraZeneca's adenovirus vector) are also being explored for various zoonotic pathogens, including **Ebola**, **Lassa fever**, and **Crimean-Congo hemorrhagic fever**.

Additionally, **veterinary vaccines** targeting zoonotic reservoirs (e.g., oral rabies vaccines for wildlife) are crucial in breaking transmission cycles and preventing spillover events.

Host-Directed Therapies and Immunomodulation

Host-directed therapies aim to **modulate the host immune response** rather than directly targeting the pathogen. These strategies are especially relevant in severe zoonotic infections characterized by dysregulated immune responses or cytokine storms.

Agents targeting host cell pathways—such as **Janus kinase (JAK) inhibitors**, **interleukin-6 (IL-6) blockers** like **tocilizumab**, and **tumor necrosis factor (TNF) inhibitors**—have been employed in severe viral infections, notably in **COVID-19** and **Ebola virus disease**, to reduce systemic inflammation and prevent multiorgan failure.

ISSN No. 2454-6194 | DOI: 10.51584/IJRIAS |Volume X Issue VI June 2025

Other host-targeted approaches include **statins**, **metformin**, and **autophagy modulators**, which have shown immunomodulatory effects and are under investigation for repurposing against various zoonotic pathogens. These therapies hold promise but require careful risk-benefit assessment due to their potential to impair protective immunity.

Case Studies and Global Impact

The global burden of zoonotic infections has come into sharp focus over the last two decades, particularly due to high-impact outbreaks that have tested the resilience of health systems worldwide. Case studies of recent zoonotic disease outbreaks, such as COVID-19 and Nipah virus, underscore the critical role of molecular diagnostics and therapeutic innovations in shaping public health responses and influencing long-term preparedness strategies.

Table 4: Case Studies of High-Impact Zoonotic Infections

Disease	Origin/Reservoir	Diagnostic Methods Used	Therapeutic Measures	Global Impact
COVID-19	Bats (likely intermediate host unknown	RT-PCR, NGS, CRISPR, serology	mRNA vaccines, monoclonal antibodies, antivirals	Global pandemic, millions of deaths, economic disruption
Nipah Virus	Fruit bats	RT-PCR, NGS	Supportive care, monoclonal antibody trials	Regional outbreaks, high mortality rates
Rabies	Dogs, bats	PCR, serology	Vaccination, post-exposure immunoglobulin	Endemic in Asia and Africa, preventable
Leptospirosis	Rodents	PCR, LAMP, ELISA	Antibiotics (doxycycline)	Global but underreported

COVID-19: Zoonosis and Molecular Response

The COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, emerged in late 2019 in Wuhan, China. Genomic analyses and epidemiological studies strongly suggest that the virus originated in animals—most likely bats—with a possible intermediate host facilitating spillover to humans. This outbreak represents one of the most significant zoonotic events in modern history.

Genomic Surveillance and Origin Tracking

Advanced molecular tools such as **next-generation sequencing (NGS)** played a pivotal role in the early characterization of the SARS-CoV-2 genome. Within weeks of the first reported cases, the complete viral genome was sequenced and shared publicly, enabling global research collaboration. Ongoing **genomic surveillance** has been essential in monitoring the emergence of variants of concern (e.g., Alpha, Delta, and Omicron), guiding public health measures and vaccine updates.

Rapid Vaccine Rollout and mRNA Technology

A major scientific milestone during the pandemic was the rapid development and deployment of **mRNA-based vaccines**, such as those by **Pfizer-BioNTech** and **Moderna**. These vaccines were developed, tested, and authorized for emergency use within a year of the virus's discovery—unprecedented in the history of vaccinology. Their success not only curbed severe disease and mortality globally but also validated **mRNA technology** as a platform for rapid-response vaccine development against other zoonotic threats.

Moreover, **PCR-based diagnostics** became the cornerstone of testing strategies worldwide, allowing early detection, isolation, and contact tracing. The pandemic highlighted the necessity of **global molecular diagnostic infrastructure**, equitable vaccine distribution, and cross-sectoral collaboration under the **One Health framework**.

ISSN No. 2454-6194 | DOI: 10.51584/IJRIAS |Volume X Issue VI June 2025

Nipah Virus: Emerging Threat

Nipah virus (NiV) is a highly pathogenic paramyxovirus classified as a priority pathogen by the World Health Organization due to its high case fatality rate (up to 75%), zoonotic origin, and potential for human-to-human transmission. First identified in 1998–99 in Malaysia, it has since caused sporadic outbreaks in Bangladesh, India, and Southeast Asia, often linked to **bat-to-human transmission** via contaminated date palm sap or contact with infected animals.

Molecular Diagnosis Using NGS and PCR

NiV outbreaks are often detected through **real-time reverse transcription PCR (RT-PCR)**, which allows for early and specific identification of the virus from human or animal samples. In addition, **NGS has been critical** for whole-genome sequencing of NiV isolates, aiding in source tracking, mutation analysis, and understanding virus evolution.

Molecular diagnostics have also been adapted for **field-deployable use**, particularly in rural and outbreak-prone areas, using LAMP and portable PCR platforms. These tools improve outbreak response times and reduce reliance on centralized labs.

Therapeutic Gaps and Ongoing Research

Currently, **no approved antivirals or vaccines** exist for Nipah virus, and treatment is limited to supportive care. However, **monoclonal antibody therapies**, such as **m102.4**, have shown efficacy in non-human primate models and have progressed to human clinical trials. Additionally, efforts are underway to develop **vector-based and mRNA vaccines** against NiV, leveraging platforms used in the COVID-19 response.

Despite its relatively limited spread compared to SARS-CoV-2, Nipah virus remains a **pandemic threat** due to its zoonotic origin, human-to-human transmissibility, and lack of widely available medical countermeasures. It exemplifies the critical need for sustained investment in **zoonotic surveillance, rapid diagnostics**, and **pre-emptive vaccine development**.

Challenges and Future Directions

Despite significant advancements in the diagnosis and treatment of zoonotic infections, several critical challenges hinder the global ability to respond rapidly and equitably to emerging threats. Addressing these limitations is essential for strengthening preparedness and ensuring sustainable health security, particularly in vulnerable populations. This section outlines key barriers and proposes future directions to improve the management of zoonotic diseases.

Limited Access to Molecular Tools in Low-Resource Settings

One of the most pressing challenges is the **unequal distribution of molecular diagnostic technologies**. Low- and middle-income countries (LMICs)—where zoonotic spillovers are most likely to occur due to high levels of human-animal interaction—often lack the infrastructure, trained personnel, and funding needed to implement and maintain advanced molecular testing platforms such as RT-PCR, NGS, or CRISPR-based diagnostics.

This disparity leads to **underdiagnosis**, **delayed outbreak response**, and **weaker surveillance systems**, creating blind spots that may facilitate the unchecked spread of pathogens. Portable and field-deployable diagnostic tools such as **LAMP assays**, **biosensor-based tests**, and **affordable point-of-care devices** need to be scaled up and adapted for these settings. In parallel, **capacity building** through workforce training and local manufacturing is crucial.

Need for Global Pathogen Surveillance Networks

Effective surveillance is fundamental for the early detection and containment of zoonotic outbreaks. However, **fragmented data systems**, **limited cross-border cooperation**, and **underreporting of cases** hinder comprehensive surveillance.

ISSN No. 2454-6194 | DOI: 10.51584/IJRIAS |Volume X Issue VI June 2025

A coordinated, **global pathogen surveillance network**—anchored in the **One Health approach**—is needed to integrate human, animal, and environmental health data. Initiatives such as the **WHO Global Genomic Surveillance Strategy** and **FAO-OIE-WHO Tripartite Collaboration** offer valuable frameworks, but require stronger funding, political commitment, and real-time data sharing mechanisms.

Furthermore, investment in **community-based surveillance**, including the use of digital tools for outbreak reporting and environmental monitoring (e.g., wildlife sampling, wastewater surveillance), can help detect spillover events before they escalate.

Integration of AI in Diagnostic Interpretation

Artificial intelligence (AI) and machine learning (ML) offer promising solutions to enhance **diagnostic efficiency, accuracy, and scalability**. AI algorithms can support **image-based diagnostics**, interpret **large-scale genomic data**, and predict **outbreak trends** using epidemiological and environmental inputs.

For instance, AI-driven platforms can assist in identifying zoonotic pathogens in sequencing data more rapidly than conventional methods, enabling real-time risk assessment during outbreaks. Integration of AI in diagnostic workflows can also reduce human error and streamline clinical decision-making, especially in high-throughput testing scenarios.

However, the deployment of AI requires **standardized data inputs**, **robust digital infrastructure**, and **ethical considerations** around data privacy and algorithmic bias.

Development of Broad-Spectrum Antivirals

The reliance on pathogen-specific therapeutics presents a major limitation during emerging zoonotic outbreaks, where there may be no existing treatment or vaccine. The development of **broad-spectrum antivirals**—agents capable of targeting multiple viruses within a family or across different viral families—could significantly enhance preparedness.

Current research focuses on identifying conserved viral proteins or host-cell pathways essential for viral replication. Promising candidates include **protease inhibitors**, **polymerase inhibitors**, and **host-targeted agents** with pan-viral activity. Broad-spectrum antivirals such as **remdesivir**, though initially developed for one virus, have shown cross-reactivity against others.

Efforts to develop **drug libraries** and **platform-based antiviral screening systems** are critical to accelerate discovery and approval pipelines. Collaborative global initiatives and public-private partnerships will be essential to translate these innovations into deployable therapies. To overcome these challenges, there must be a **coordinated global effort** that combines technological innovation with political will, equitable funding, and sustainable health systems development. Strengthening diagnostic infrastructure, enhancing surveillance capacity, and promoting research into novel therapeutics—particularly in high-risk regions—are imperative to reduce the global burden of zoonotic diseases and prevent future pandemics.

CONCLUSION

The emergence and re-emergence of zoonotic infections continue to pose significant threats to global health, economies, and ecosystems. The integration of **molecular diagnostics** and **innovative therapeutic strategies** has dramatically enhanced our capacity to detect, monitor, and manage these infections with greater speed, accuracy, and precision than ever before. Technologies such as PCR, LAMP, NGS, CRISPR-based diagnostics, and biosensor platforms have revolutionized pathogen identification and outbreak tracking, while novel therapies—including monoclonal antibodies, mRNA vaccines, and host-directed treatments—are reshaping the landscape of clinical management.

Despite these advancements, considerable challenges remain—particularly in ensuring **equitable access** to molecular tools, expanding **real-time surveillance networks**, and developing **broad-spectrum countermeasures** that can rapidly respond to emerging pathogens. The threat of future pandemics, as

illustrated by COVID-19 and other high-consequence zoonoses like Nipah virus, underscores the urgent need for sustained global investment and innovation.

A **One Health approach**, which recognizes the interconnectedness of human, animal, and environmental health, must be central to future strategies. This requires **multisectoral collaboration**, **data sharing**, **capacity building in low-resource settings**, and **robust research ecosystems** capable of rapid response.

In conclusion, while molecular diagnostics and next-generation therapeutics have transformed our capabilities, their full potential can only be realized through **integrated, inclusive, and forward-looking global health frameworks**. Continued progress will depend not only on scientific advancement but also on political commitment and international solidarity to preempt and mitigate the impact of zoonotic diseases worldwide.

REFERENCES

1. Saker, L.; Lee, K.; Cannito, B.; Gilmore, A.; Campbell-Lendrum, D.; Phil, D. Globalization and infectious diseases: A review of the linkages. World Health Organization 2004. Available online: https://apps.who.int/iris/handle/10665/68726 (accessed on 15 January 2020).WHO. List of Blueprint Priority Diseases. 2018 Annual Review. 2019. Available online: https://www.who.int/blueprint/priority-diseases/en/ (accessed on 16 August 2019).Centers for Disease Control and Prevention. Antibiotic Resistant Threats in the United States 2019. Available online: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf (accessed on 15 January 2020).
2. Cassini, A.; Högberg, L.D.; Plachouras, D.; Quattrocchi, A.; Hoxha, A.; Simonsen, G.S.; Colomb-Cotinat, M.; Kretzschmar, M.E.; Devleesschauwer, B.; Cecchini, M.; et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. Lancet Infect. Dis. 2019, 19, 56–66. [Google Scholar] [CrossRef] [Green Version]
3. Ayukekbong, J.A.; Ntemgwa, M.; Atabe, A.N. The threat of antimicrobial resistance in developing countries: Causes and control strategies. Antimicrob. Resist. Infect. Cont. 2017, 6, 47. [Google Scholar] [CrossRef] [PubMed]
4. Zhu, C.S.; Liu, C.Y.; Qiu, X.Y.; Xie, S.S.; Li, W.Y.; Zhu, L.; Zhu, L.Y. Novel nucleic acid detection strategies based on CRISPR-Cas systems: From construction to application. Biotechn. Bioeng. 2020, 117, 2279–2294. [Google Scholar] [CrossRef] [PubMed]
5. Lai, C.C.; Shih, T.P.; Ko, W.C.; Tang, H.J.; Hsueh, P.R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents 2020, 55, 105924. [Google Scholar] [CrossRef] [PubMed]
6. CenterWatch. FDA Approved Drugs. 2020. Available online: https://www.centerwatch.com/directories/1067-fda-approved-drugs/topic/546-bacterial-infections (accessed on 10 January 2020).
7. Funke, G.; Funke-Kissling, P. Evaluation of the new VITEK 2 card for identification of clinically relevant gram-negative rods. J. Clin. Microbiol. 2004, 42, 4067–4071. [Google Scholar] [CrossRef] [Green Version]
8. Martinez, R.M.; Wolk, D.M. Bloodstream infections. Microbiol. Spectr. 2016, 4, 4. [Google Scholar] [CrossRef] [Green Version]
9. Chowdhury, I.H.; Sen, A.; Bahar, B.; Hazra, A.; Chakraborty, U.; Choudhuri, S.; Goswami, A.; Pal, N.K.; Bhattacharya, B. A molecular approach to identification and profiling of first-line-drug-resistant mycobacteria from sputum of pulmonary tuberculosis patients. J. Clin. Microbiol. 2012, 50, 2082–2084. [Google Scholar] [CrossRef] [Green Version]
10. Reja, A.H.; Biswas, N.; Biswas, S.; Dasgupta, S.; Chowdhury, I.H.; Banerjee, S.; Chakraborty, T.; Dutta, P.K.; Bhattacharya, B. Fite-Faraco staining in combination with multiplex polymerase chain reaction: A new approach to leprosy diagnosis. Indian J. Derm. Venereol. Leprol. 2013, 79, 693–700. [Google Scholar] [CrossRef]
11. Iha, K.; Inada, M.; Kawada, N.; Nakaishi, K.; Watabe, S.; Tan, Y.H.; Shen, C.; Ke, L.-Y.; Yoshimura, T.; Ito, E. Ultrasensitive ELISA developed for diagnosis. Diagnostics 2019, 9, 78. [Google Scholar] [CrossRef] [Green Version]

12. Sakashita, K.; Takeuchi, R.; Takeda, K.; Takamori, M.; Ito, K.; Igarashi, Y.; Hayashi, E.; Iguchi, M.; Ono, M.; Kashiyama, T.; et al. Ultrasensitive enzyme-linked immunosorbent assay for the detection of MPT64 secretory antigen to evaluate Mycobacterium tuberculosis viability in sputum. Int. J. Infect. Dis. 2020, 96, 244–253. [Google Scholar] [CrossRef]
13. Salimnia, H.; Fairfax, M.R.; Lephart, P.R.; Schreckenberger, P.; DesJarlais, S.M.; Johnson, J.K.; Robinson, G.; Carroll, K.C.; Greer, A.; Morgan, M.; et al. Evaluation of the FilmArray blood culture identification panel: Results of a multicenter controlled trial. J. Clin. Microbiol. 2016, 54, 687–698. [Google Scholar] [CrossRef] [PubMed] [Green Version]
14. Li, H.; Bai, R.; Zhao, Z.; Tao, L.; Ma, M.; Ji, Z.; Jian, M.; Ding, Z.; Dai, X.; Bao, F.; et al. Application of droplet digital PCR to detect the pathogens of infectious diseases. Biosci Rep. 2018, 38, BSR20181170. [Google Scholar] [CrossRef] [PubMed] [Green Version]
15. Ecker, D.J.; Massire, C.; Blyn, L.B.; Hofstadler, S.A.; Hannis, J.C.; Eshoo, M.W.; Hall, T.A.; Sampath, R. Molecular genotyping of microbes by multilocus PCR and mass spectrometry: A new tool for hospital infection control and public health surveillance. Methods Mol. Biol. 2009, 13, e0197436. [Google Scholar] [CrossRef]
16. Wilson, M.R.; O'Donovan, B.D.; Gelfand, J.M.; Sample, H.A.; Chow, F.C.; Betjemann, J.P.; Shah, M.P.; Richie, M.B.; Gorman, M.P.; Hajj-Ali, R.A.; et al. Chronic meningitis investigated via metagenomic next-generation sequencing. JAMA Neurol. 2018, 75, 947–955. [Google Scholar] [CrossRef]
17. Zhang, X.; Wu, Z.; Wang, K. Diagnosis of Streptococcus suis meningoencephalitis with metagenomic next-generation sequencing of the cerebrospinal fluid: A case report with literature review. BMC Infect. Dis. 2020, 20, 884. [Google Scholar] [CrossRef]
18. Petersen, L.M.; Martin, I.W.; Moschetti, W.E.; Kershaw, C.M.; Tsongalis, G.J. Third generation sequencing in the clinical laboratory: Exploring the advantages and challenges of nanopore sequencing. J. Clin. Microbiol. 2020, 58, e01315–e01319. [Google Scholar] [CrossRef]
19. Vincent, M.; Xu, Y.; Kong, H. Helicase-dependent isothermal DNA amplification. EMBO Rep. 2004, 5, 795–800. [Google Scholar] [CrossRef]
20. Notomi, T.; Okayama, H.; Masubuchi, H.; Yonekawa, T.; Watanabe, K.; Amino, N.; Hase, T. Loop-mediated isothermal amplification of DNA. Nucleic. Acids Res. 2000, 28, E63. [Google Scholar] [CrossRef] [Green Version]
21. Guatelli, J.C.; Whitfield, K.M.; Kwoh, D.Y.; Barringer, K.J.; Richman, D.D.; Gingeras, T.R. Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. Proc. Natl. Acad. Sci. USA 1990, 87, 1874–1878. [Google Scholar] [CrossRef] [Green Version]
22. Lizardi, P.M.; Huang, X.; Zhu, Z.; Bray-Ward, P.; Thomas, D.C.; Ward, D.C. Mutation detection and single-molecule counting using isothermal rolling-circle amplification. Nat. Genet. 1998, 19, 225–232. [Google Scholar] [CrossRef]
23. Kozel, T.R.; Burnham-Marusich, A.R. Point-of-care testing for infectious diseases: Past, present, and future. J. Clin. Microbiol. 2017, 55, 2313–2320. [Google Scholar] [CrossRef] [PubMed] [Green Version]
24. Blair, E.O.; Corrigan, D.K. A review of microfabricated electrochemical biosensors for DNA detection. Biosens. Bioelectron. 2019, 1, 57–67. [Google Scholar] [CrossRef] [PubMed] [Green Version]
25. Usachev, E.V.; Usacheva, O.V.; Aganovski, I.E. Surface plasmon resonance-based bacterial aerosol detection. J. App. Microbiol. 2014, 17, 1655–1662. [Google Scholar] [CrossRef] [PubMed]
26. Yeh, Y.; Zhang, Y.; Sabestien, A.; Chou, T.; Zhou, B.; Zhong, L.; Albert, I.; Lu, H.; Swaminathan, V.; Ghedin, E.; et al. A rapid and label-free platform for virus capture and identification from clinical samples. Proc. Natl. Acd. Sci. USA 2020, 117, 895–901. [Google Scholar] [CrossRef] [Green Version]
27. Rafael, M.E.; Taylor, T.; Magill, A.; Lim, Y.W.; Girosi, F.; Allan, R. Reducing the burden of childhood malaria in Africa: The role of improved. Nature 2006, 1, 39–48. [Google Scholar] [CrossRef]
28. Nasseri, B.; Soleimani, N.; Rabiee, N.; Kalbasi, A.; Karimi, M.; Hambling, M.R. Point-of-care microfluidic devices for pathogen detection. Biosen. Bioelectron. 2018, 117, 112–128. [Google Scholar] [CrossRef]

29. Rodriguez-Manzano, J.; Moser, N.; Malpartida-Cardenas, K.; Moniri, A.; Fisarova, L.; Pennisi, I.; Boonyasiri, A.; Jauneikaite, E.; Abdolrasouli, A.; Otter, J.A.; et al. Rapid detection of mobilized colistin resistance using a nucleic acid based Lab-on-a-Chip diagnostic system. Sci. Rep. 2020, 10, 8448. [Google Scholar] [CrossRef]
30. WHO. 2017. Available online: https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed (accessed on 15 January 2020).
31. Creech, C.B.; Frenck, R.W.; Fiquet, A.; Feldman, R.; Kankam, M.K.; Pathirana, S.; Baber, J.; Radley, D.; Cooper, D.; Eiden, J.; et al. Persistence of immune responses through 36 months in healthy adults after vaccination with a novel Staphylococcus aureus 4-Antigen Vaccine (SA4Ag). Open Forum. Infect. Dis. 2020, 7, ofz532. [Google Scholar] [CrossRef] [Green Version]
32. Kay, E.; Cuccui, J.; Wren, B.W. Recent advances in the production of recombinant glycoconjugate vaccines. NPJ Vaccines 2019, 4, 16. [Google Scholar] [CrossRef]
33. Ingolotti, M.; Kawalekar, O.; Shedlock, D.J.; Muthumani, K.; Weiner, D.B. DNA vaccines for targeting bacterial infections. Expert Rev. Vaccines 2010, 9, 747–763. [Google Scholar] [CrossRef] [Green Version]
34. Caskey, M.; Lefebvre, F.; Filali-Mouhim, A.; Cameron, M.J.; Goulet, J.P.; Haddad, E.K.; Breton, G.; Trumpfheller, C.; Pollak, S.; Shimeliovich, I.; et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J. Exp. Med. 2011, 208, 2357–2366. [Google Scholar] [CrossRef] [PubMed]
35. Diaz Blanco, C.; Ortner, A.; Dimitrov, R.; Navarro, A.; Mendoza, E.; Tzanov, T. Building an antifouling zwitterionic coating on urinary catheters using an enzymatically triggered bottom-up approach. ACS Appl. Mater Interfaces 2014, 6, 11385–11393. [Google Scholar] [CrossRef] [PubMed]
36. Murugayah, S.A.; Gerth, M.L. Engineering quorum quenching enzymes: Progress and perspectives. Biochem. Soc. Trans. 2019, 47, 793–800. [Google Scholar] [CrossRef] [PubMed]
37. Defraine, V.; Fauvart, M.; Michiels, J. Fighting bacterial persistence: Current and emerging anti-persister strategies and therapeutics. Drug Resist Updat. 2018, 38, 12–26. [Google Scholar] [CrossRef]
38. Parlet, C.P.; Kavanaugh, J.S.; Crosby, H.A.; Raja, H.A.; El-Elimat, T.; Todd, D.A.; Pearce, C.J.; Cech, N.B.; Oberlies, N.H.; Horswill, A.R. Apicidin attenuates MRSA virulence through quorum-sensing inhibition and enhanced host defense. Cell Rep. 2019, 27, 187–198.e6. [Google Scholar] [CrossRef] [Green Version]
39. Hentzer, M.; Eberl, L.; Nielsen, J.; Givskov, M. Quorum sensing: A novel target for the treatment of biofilm infections. BioDrugs 2003, 17, 241–250. [Google Scholar] [CrossRef]
40. Fleming, D.; Chahin, L.; Rumbaugh, K. Glycoside hydrolases degrade polymicrobial bacterial biofilms in wounds. Antimicrob. Agents Chemother. 2017, 61, e01998-16. [Google Scholar] [CrossRef] [Green Version]
41. Bush, K.; Bradford, P.A. Interplay between β-lactamases and new β-lactamase inhibitors. Nat. Rev. Microbiol. 2019, 17, 295–306. [Google Scholar] [CrossRef]
42. Grimsey, E.M.; Fais, C.; Marshall, R.L.; Ricci, V.; Ciusa, M.L.; Stone, J.W.; Ivens, A.; Malloci, G.; Ruggerone, P.; Vargiu, A.V.; et al. Chlorpromazine and amitriptyline are substrates and inhibitors of the acrb multidrug efflux pump. MBio 2020, 11, e00465-20. [Google Scholar] [CrossRef]
43. Fukumoto, A.; Kim, Y.P.; Hanaki, H.; Shiomi, K.; Tomoda, H.; Omura, S. Cyslabdan, a new potentiator of imipenem activity against methicillin-resistant Staphylococcus aureus, produced by Streptomyces sp. K04-0144: II. Biological activities. J. Antibiot (Tokyo) 2008, 61, 7–10. [Google Scholar] [CrossRef] [Green Version]
44. Nieves, I.; Hally, C.; Viappiani, C.; Agut, M.; Nonell, S. A porphycene-gentamicin conjugate for enhanced photodynamic inactivation of bacteria. Bioorg. Chem. 2020, 97, 103661. [Google Scholar] [CrossRef] [PubMed]
45. Feng, Y.; Palanisami, A.; Ashraf, S.; Bhayana, B.; Hasan, T. Photodynamic inactivation of bacterial carbapenemases restores bacterial carbapenem susceptibility and enhances carbapenem antibiotic effectiveness. Photodiagnosis Photodyn. 2020, 30, 101693. [Google Scholar] [CrossRef] [PubMed]
46. Cheng, Y.S.; Sun, W.; Xu, M.; Shen, M.; Khraiwesh, M.; Sciotti, R.J.; Zheng, W. Repurposing screen identifies unconventional drugs with activity against multidrug resistant Acinetobacter baumannii. Front. Cell Infect. Microbiol. 2019, 8, 438. [Google Scholar] [CrossRef]

47. Talele, T.T.; Khedkar, S.A.; Rigby, A.C. Successful applications of computer aided drug discovery: Moving drugs from concept to the clinic. Curr. Top. Med. Chem. 2010, 10, 127–141. [Google Scholar] [CrossRef] [PubMed]
48. Batalha, I.L.; Bernut, A.; Schiebler, M.; Ouberai, M.M.; Passemar, C.; Klapholz, C.; Kinna, S.; Michel, S.; Sader, K.; Castro-Hartmann, P.; et al. Polymeric nanobiotics as a novel treatment for mycobacterial infections. J. Control. Release 2019, 314, 116–124. [Google Scholar] [CrossRef] [PubMed]
49. Sánchez-López, E.; Gomes, D.; Esteruelas, G.; Bonilla, L.; Lopez-Machado, A.L.; Galindo, R.; Cano, A.; Espina, M.; Ettcheto, M.; Camins, A.; et al. Metal-based nanoparticles as antimicrobial agents: An overview. Nanomaterials 2020, 10, 292. [Google Scholar] [CrossRef] [PubMed] [Green Version]
50. Skoura, N.; Wang-Jairaj, J.; Della Pasqua, O.; Chandrasekaran, V.; Billiard, J.; Yeakey, A.; Smith, W.; Steel, H.; Tan, L.K. Effect of raxibacumab on immunogenicity of Anthrax Vaccine Adsorbed: A phase 4, open-label, parallel-group, randomised non-inferiority study. Lancet Infect. Dis. 2020, 20, 983–991. [Google Scholar] [CrossRef]
51. Wilcox, M.H.; Gerding, D.N.; Poxton, I.R.; Kelly, C.; Nathan, R.; Birch, T.; Cornely, O.A.; Rahav, G.; Bouza, E.; Lee, C.; et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N. Engl. J. Med. 2017, 376, 305–317. [Google Scholar] [CrossRef]
52. Marshall, N.C.; Brett Finlay, B. Targeting the type III secretion system to treat bacterial infections. Expert Opin. Targets 2014, 18, 137–152. [Google Scholar] [CrossRef]
53. Saleh, M.M.; Sadeq, R.A.; Abdel Latif, H.K.; Abbas, H.A.; Askoura, M. Zinc oxide nanoparticles inhibits quorum sensing and virulence in Pseudomonas aeruginosa. Afr. Health Sci. 2019, 19, 2043–2055. [Google Scholar] [CrossRef] [Green Version]
54. DiGiandomenico, A.; Keller, A.E.; Gao, C.; Rainey, G.J.; Warrener, P.; Camara, M.M.; Bonnell, J.; Fleming, R.; Bezabeh, B.; Dimasi, N.; et al. A multifunctional bispecific antibody protects against Pseudomonas aeruginosa. Sci. Transl. Med. 2014, 6, 262ra155. [Google Scholar] [CrossRef] [PubMed]
55. Varshney, A.K.; Kuzmicheva, G.A.; Lin, J.; Sunley, K.M.; Bowling, R.A., Jr.; Kwan, T.Y.; Mays, H.R.; Rambhadran, A.; Zhang, Y.; Martin, R.L.; et al. A natural human monoclonal antibody targeting Staphylococcus protein A protects against Staphylococcus aureus bacteremia. PLoS ONE 2018, 13, e0190537. [Google Scholar] [CrossRef] [PubMed] [Green Version]
56. Liu, L.; Zhou, L.; Li, Y.; Bai, W.; Liu, N.; Li, W.; Gao, Y.; Liu, Z.; Han, R. High-density lipoprotein acts as an opsonin to enhance phagocytosis of group A Streptococcus by U937 cells. Microbiol. Immunol. 2015, 59, 419–425. [Google Scholar] [CrossRef] [PubMed] [Green Version]
57. Pirnay, J.P.; Verbeken, G.; Ceyssens, P.J.; Huys, I.; De Vos, D.; Ameloot, C.; Fauconnier, A. The Magistral Phage. Viruses 2018, 10, 64. [Google Scholar] [CrossRef] [Green Version]
58. Ferry, T.; Boucher, F.; Fevre, C.; Perpoint, T.; Chateau, J.; Petitjean, C.; Josse, J.; Chidiac, C.; L'hostis, G.; Leboucher, G.; et al. Innovations for the treatment of a complex bone and joint infection due to XDR Pseudomonas aeruginosa including local application of a selected 59.cocktail of bacteriophages. J. Antimicrob. Chemother. 2018, 73, 2901–2903. [Google Scholar] [CrossRef] [Green Version]